On Monday, Shares of Ares Capital Corporation (NASDAQ:ARCC), added 0.26% and closed at $15.54 in the last trading session. The last trading range of the stock ranges between $15.48 and $15.60.
Sarepta Therapeutics Inc (NASDAQ:SRPT), dropped -0.75% and closed at $60.95 in the last trading session. The last trading range of the stock ranges between $60.10 and $61.80. The company’s Market capitalization is $3.25 Billion with the total Outstanding Shares of 52.89 million. Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company (“Catabasis”), and Sarepta Therapeutics, Inc. (SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics (“Sarepta”), recently declared a joint research partnershipto explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD). The two companies will contribute their respective expertise to study an exon skipping treatment developed by Sarepta, together with an oral NF-kB inhibition treatment developed by Catabasis in a mouse model of DMD.
“We are excited to work with Sarepta on this joint research collaboration, which to our knowledge is the first time two companies are testing a combination of investigational therapies to treat Duchenne. Although we believe edasalonexent (CAT-1004) has the potential to be a disease-modifying monotherapy, we think there is benefit to exploring innovative ways to make the most meaningful difference in this devastating disease”, said Jill C. Milne, Ph.D., chief executive officer of Catabasis. “In addition to our continued development of edasalonexent, we are happy to take the first step via this partnershipto determine if edasalonexent may be complementary to an exon-skipping treatment strategy in the treatment of DMD using a preclinical model.”
“We recognize the extreme unmet medical need in DMD and are committed to determining the best treatment strategies for patients affected by Duchenne,” said Edward Kaye, M.D., Sarepta’s chief executive officer. “We believe exon skipping has the potential to target the underlying genetic cause of the disease by restoring the mRNA reading frame to produce dystrophin in skeletal muscle. We are happy to initiate activities with Catabasis to evaluate a potential combination treatment approach of exon-skipping and NF-kB inhibition in DMD.”
Nielsen N.V. Ordinary Shares (NYSE:NLSN), gained 0.15% and closed at $53.65 in the last trading session. The last trading range of the stock ranges between $53.25 and $53.75. During the 52-week trading session the minimum price at which share price traded, registered at $42.90 and reached to max level of $55.94. Recently, Nielsen declared that as part of its ongoing effort to advance television measurement, it will expand the use of its Portable People Meter™ (PPM) technology to provide direct persons measurement for Local TV ratings. The addition of PPM panelists to Local TV service will effectively double the sample size and provide local clients with ratings that reflect precise measurement of local viewing behaviors and insights, and boost ratings fidelity. Nielsen will begin to introduce PPM measurement for in-home and out-of-home viewing in 2017.
PPM is used recently for Nielsen’s market-leading Audio measurement service and will be extended for use in Local TV ratings which will now include viewing from over 75,000 PPM panelists across 44 Local TV markets. This enhancement is estimated to lead to a 40% decrease in zero audience estimates, providing local TV clients with raised opportunities to monetize their in-home and out-of-home viewing audiences.
“As part of our overall local market enhancement measurement strategy, Nielsen is maximizing the strengths of various data sets, counting PPM data and Return Path Data, to assist our local clients understand their total audience by capturing all sources of viewing. In Addition To, we are providing them with the tools needed to maximize their audience and grow their business,” said Megan Clarken, President, Nielsen Product Leadership. “The media industry is in the midst of an important transition and people have endless options for viewing their favorite content. We are the only measurement provider that can directly measure the out-of-home television audience.”